Visão geral da empresa
Inventiva S.A. operates as a clinical-stage biopharmaceutical entity dedicated to the research and development of oral small molecule therapies designed to treat metabolic dysfunction-associated steatohepatitis (MASH) and other specific diseases within the French and international markets. The company is positioned within the broader Healthcare sector and specifically functions in the Biotechnology industry, a classification that signifies its focus on biological sciences to create innovative medical treatments rather than manufacturing generic goods. According to available market data, the company holds a total market capitalization of $1.10 billion and reported trailing twelve-month revenues of $7.93 million, while the specific count of its employees is not disclosed in the provided financial records. These valuation and revenue figures indicate that Inventiva S.A. is a mid-cap enterprise operating with a revenue base that is substantial for a clinical-stage biotech but represents a significant portion of its total market value, suggesting that investor pricing is heavily influenced by potential pipeline value rather than current cash generation.
Saúde financeira
The company reported trailing twelve-month revenues of $7.93 million alongside a net income loss of $354,137,984 and an EBITDA deficit of $138,856,000. The substantial gap between the positive revenue figure of $7.93 million and the severe net income loss reveals a cost structure characterized by high operating expenses that far exceed current sales, a common pattern in early-stage drug development where research costs outweigh immediate revenue. Regarding liquidity and flexibility, the free cash flow metric is not available in the current financial dataset, which prevents a definitive assessment of the company's ability to fund operations without external capital injections. The gross margin stands at 100.0%, indicating that the company has not yet incurred significant cost of goods sold relative to its sales, likely due to the pre-commercial nature of its product pipeline. Conversely, the operating margin is -3686.1% and the profit margin is 0.0%, reflecting the intense burn rate typical of biotechnology firms developing novel therapies like Lanifibranor. In terms of leverage, the specific figures for total cash, total debt, and debt-to-equity ratio are not disclosed, rendering a direct comparison of conservative versus leveraged balance sheet strategies impossible based on the available data. Furthermore, the current ratio is not provided, so an evaluation of short-term liquidity relative to current liabilities cannot be performed. Similarly, the return on equity and return on assets metrics are unavailable, meaning the effectiveness of management in generating returns on shareholder equity or total assets cannot be quantified at this time.
Avaliação de valorização
The valuation profile of Inventiva S.A. presents a trailing P/E ratio that is not applicable due to negative earnings, while the forward P/E ratio is listed at -4.17. The existence of a negative forward P/E implies that analysts or market data providers expect the company to remain unprofitable in the coming year, preventing a traditional earnings-based valuation trajectory from being established. The price-to-book ratio is recorded at -72.28, a negative figure that indicates the market price is significantly below the book value or that the book value itself is negative due to accumulated losses, suggesting a market discount that reflects the high risk associated with the company's developmental stage. Alternative valuation metrics include a price-to-sales ratio of 138.85 and an EV/EBITDA ratio that is not applicable, which collectively suggest that the market is valuing the company primarily on its sales potential and intellectual property rather than its current profitability or enterprise value relative to earnings. The stock price has historically ranged between a 52-week low of $2.85 and a 52-week high of $7.98, providing a historical context for price volatility independent of the broader market. The beta value is 0.95, which indicates that the stock's price volatility tracks closely with the movement of the broader market, showing neither significant defensive characteristics nor excessive aggression compared to the overall market index.
Growth & Income
The revenue growth year-over-year is reported at -79.6%, while the earnings growth year-over-year is not applicable due to the absence of comparable prior period earnings in the dataset. This negative revenue growth rate suggests a contraction in sales, which, when paired with the lack of positive earnings growth, implies that the company is currently facing challenges in scaling its commercial efforts or maintaining sales volume relative to the previous year. As the company does not pay a dividend, the dividend yield is not applicable and the payout ratio is 0.0%, meaning the company retains all of its earnings or losses to reinvest into its clinical development pipeline and operational growth rather than distributing income to shareholders. This reinvestment strategy is typical for clinical-stage biopharmaceutical companies that prioritize funding their research programs, such as the development of Lanifibranor, over returning capital to investors. Consequently, the overall growth and income profile for Inventiva S.A. is characterized by a lack of current income distribution and a reliance on future value creation to offset the significant decline in recent revenue figures.